Pharmaxis cheers win for drug

Company News

Pharmaxis Limited (ASX:PXS) says the Australian Government has given the green light for its cystic fibrosis drug bronchitol to have simplified access to the Pharmaceutical Benefits Scheme.
The decision removes the need for patients to demonstrate an increase in lung function to secure a PBS reimbursement.
Under the new listing, the criteria will be set by the doctor and patient to allow flexibility in clinical decision-making.
Pharmaxis CEO Gary Phillips says the decision simplifies the process for patients and offers doctors more flexibility in their approach to treating cystic fibrosis.
Pharmaxis booked a net loss of $20.7 million in the first half of fiscal 2013.

Are you a 708 sophisticated investor?

A sophisticated investor is defined under Section 708 of the Corporations Act (net assets of $2.5 million or annual incomes in excess of $250,000).

They are eligible to receive information regarding wholesale investment opportunities that are not available to regular or retail investors.

Please subscribe if you would like to be alerted to these types of opportunities.